LONDON - Shire Ltd. is buying Jerini AG in a cash deal valuing the German company at €328 million (US$519 million) to acquire Firazyr, (Icatibant) a treatment for hereditary angioedema (HAE), which is due to be launched in Europe by the end of the year. (BioWorld Today) Read More
